1999 article
"Despite a relatively strong public research base, the ability of Australian companies to develop
and commercialise scientific discovery is generally weak. The start-up of fledgling businesses is
expensive and commercial opportunities are often sold prematurely to produce a necessary
injection of funds. There is little support for creation of small business infrastructure. In sales or
licensing agreements, Australian medical biotechnology enterprises are often in a weak
negotiating position as they do not have the level of corporate experience available to the larger
partner. There is a lack of good business management expertise and a lack of good accounting
and legal advice relevant to the medical biotechnology sector. Although some of the larger firms
are starting to develop this expertise, Australia is still a long way behind Europe and the US.
Thus, for a variety of reasons, many of Australia's smaller and medium sized biotechnology
companies are constrained in their ability to grow and thereby prevent Australia from capturing
Strategic Partnerships with Industry - Research and Training Scheme supports collaboration between universities
and industry."
"This paper was prepared by an independent working group for PMSEIC. Its views are those of
the Working Group, not necessarily those of the Commonwealth
full economic returns from the resources, both capital and intellectual, vested in its fundamental
research institutions."
http://www.chiefscientist.gov.au/wp-content/uploads/1990625-Innovation-in-Medical-Biotechnology.pdf
- Forums
- ASX - By Stock
- BTA
- nothing has changed for bta imho
nothing has changed for bta imho
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online